Stuart Miller, MD, is an orthopedic surgeon at MedStar Union Memorial Hospital and assistant professor at Johns Hopkins University School of Medicine, both based in Baltimore.
Biogennix named Michael Roux as the orthobiologic company's new general manager.
The global platelet rich plasma market is expected to hit $400 million by 2023, growing at a 13.3 percent compound annual growth rate, according to a Qurate Business Intelligence report.
The global orthopedic biomaterials market is expected to grow at a 7 percent compound annual growth rate between 2018 and 2022, according to a Technavio report.
Bioventus launched its Osteomatrix+ bone graft for various spine and orthopedic applications.
Orthopedic fixation company Ossio received FDA 510(k) clearance for its Ossiofiber Bone Pin Family.
Marco Rodriguez, MD, founder of Baton Rouge, La.-based International Spine Institute, is using regenerative stem cell therapies as an alternative to spinal surgery.
Generex Biotechnology Corp. signed a letter to purchase Medisource Partners, an FDA-registered distributor.
SpinalCyte received a new Australian patent related to its fibroblast technology.
DiscGenics' injectable disc cell therapy, IDCT, passed the initial safety review of its first-in-human trial for moderate degenerative disc disease treatment.